Company Analysis
Sign in

Scholar Rock Holding Corporation (SRRK)

Nasdaq: SRRK · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 2018
Full chart Alerts Compare
Grade4.8
◀ Past 3.8● Present 4.3▶ Future 5.8
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

30 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Scholar Rock Holding Corporation’s names, not what it holds today.

Patents granted
30
30 utility, 1976 to Dec 31, 2025
Granted in 2025
6
Against 4 in 2024 and 2 in 2023
Applications published
62
7 of them in 2025
Names they are printed under
2
a subsidiary
By yearGrantedApplications published
'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals19
Biotechnology2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Scholar Rock, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
55 published
Scholar Rock, Inc. a subsidiary
US, as the owner printed on each patent
30 granted
7 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 28, 202512,454,570Compositions and methods for growth factor modulationPharmaceuticalsScholar Rock, Inc.
Jul 15, 202512,358,992LTBP complex-specific inhibitors of TGF-beta 1 and uses thereofBiotechnologyScholar Rock, Inc.
Jun 24, 202512,338,279Selective and potent inhibitory antibodies of myostatin activationPharmaceuticalsScholar Rock, Inc.
May 13, 202512,297,262RGMC-selective inhibitors and use thereofBiotechnologyScholar Rock, Inc.
Apr 22, 202512,281,159TGFβ antibodies, methods and usesPharmaceuticalsScholar Rock, Inc.
Mar 18, 202512,252,531Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitorsPharmaceuticalsScholar Rock, Inc.
Dec 24, 202412,173,059LTBP complex-specific inhibitors of TGFβ and uses thereofPharmaceuticalsScholar Rock, Inc.
Oct 22, 202412,122,823Isoform-selective TGFB1 inhibitors and use thereofPharmaceuticalsScholar Rock, Inc.
Jun 11, 202412,006,359Methods for altering body composition by administering anti-pro/latent myostatin antibodiesPharmaceuticalsScholar Rock, Inc.
Mar 12, 202411,925,683Compositions for making and using anti-Myostatin antibodiesPharmaceuticalsScholar Rock, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 23, 20252025/0326827USE OF MYOSTATIN INHIBITOR FOR TREATING SPINAL MUSCULAR ATROPHYPharmaceuticalsScholar Rock, Inc.
Oct 2, 20252025/0304669RGMC-SELECTIVE INHIBITORS AND USE THEREOFBiotechnologyScholar Rock, Inc.
Sep 11, 20252025/0282857TGF-BETA INHIBITORS AND USE THEREOFPharmaceuticalsScholar Rock, Inc.
Aug 14, 20252025/0257125HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOFPharmaceuticalsScholar Rock, Inc.
Jul 3, 20252025/0215072ISOFORM-SELECTIVE TGFB1 INHIBITORS AND USE THEREOFPharmaceuticalsScholar Rock, Inc.
Jun 5, 20252025/0179164LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOFPharmaceuticalsScholar Rock, Inc.
Apr 17, 20252025/0122274SELECTIVE AND POTENT INHIBITORY ANTIBODIES OF MYOSTATIN ACTIVATIONPharmaceuticalsScholar Rock, Inc. · patent 12,338,279 granted from it
Nov 28, 20242024/0391989METHODS FOR INHIBITING MYOSTATIN ACTIVATION BY ADMINISTERING ANTI-PRO/LATENT MYOSTATIN ANTIBODIESPharmaceuticalsScholar Rock, Inc.
Nov 14, 20242024/0374718ANTI-PRO/LATENT-MYOSTATIN ANTIBODIES AND USES THEREOFPharmaceuticalsScholar Rock, Inc.
Nov 7, 20242024/0368262A MYOSTATIN PATHWAY INHIBITOR IN COMBINATION WITH A GLP-1 PATHWAY ACTIVATOR FOR USE IN TREATING METABOLIC DISORDERSPharmaceuticalsScholar Rock, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 14 · Biotechnology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton SRRK · research, not advice